5-hydroxymethylcytosine binding, ES cell specificGenealiases: C3orf37 · DC12 · SRAPD1
Q-omics provides the consensus-scored HMCES profile across patient tissues and cancer cell-line models. HMCES expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HMCES is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, HMCES protein abundance shows 22,164 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where HMCES shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMCES — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMCES survival associations across molecular data types. HMCES RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMCES RNA expression–survival associations across cancer types. High HMCES expression shows unfavorable associations in KICH, LIHC, ACC and PAAD, but favorable associations in UVM and CESC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HMCES RNA expression.
This table summarizes HMCES tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HMCES. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMCES shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, LUSC, STAD and THCA. The HNSC box plot shows higher HMCES RNA expression in tumor versus normal tissue (log2 FC = +1.310, t-test p < 0.001).
This table shows molecular features associated with HMCES in patient tissues and cancer cell lines. In patient samples, HMCES shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HMCES RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
